Many projections as to mkt potential for anti scarring. 1 1/2- 3B about the average from all the projections I've seen. Must consider the more therapeutic the greater the market IMO.
If the guesstimates are even half on target, it's at or near blockbuster levels. As was mentioned on the board earlier, that is for scarring alone. The applications make this "platform tech" far outweigh skin scarring as has been discussed here before, keeping in mind the "platform tech" that will result, lest not discount the "delivery tecnology" as well.
Exciting prospects for a $35M m/cap company with expert management I'd say........Good weekend All......
Where was there mention of amending any trial. the only recent news was the design of a third P2 trial a few weeks ago.......................GLTA
Think your missing the point wallst. I am not equating skin healing with rxi-109. Simply stating that normal sin healing from incision is relatively quick vs testing therapies in most other trials. As evidenced by the fact that we are near completion of P2. Just review how quickly P1 concluded.......GLTA
Good post rjlmiss, I had the very same thought at the time of the spin off...........GL
Absolutely not. I refer to the time it takes for an incision to heal as it relates to the timeline of these trials versus trials of internal administered compounds and the time required to prove effectiveness.
Simply put, rxi-109 trials are greatly expedited due to the testing itself..........GLTA
RXI has gone through P1 and near end of P2 in under two years. Not sure how many are aware just how fast that is. Attributable to quickness of skin healing along with readily visible results. Quite a different scenario from most drug trials. Most would have taken 3-5 times as long.
Credit to Cauwenbergh who chose to take on the task of heading RXI, knowing the nearer term potential. (mu guess here). We have yet to get updated on the scope of the platform this could produce. News will be soon. Just my thought this afternoon.....GLTA
Think I may be mistaken and caught wrong screen, but I do see 16.12m on both Ihub and Finviz? Sorry for the false alarm gents.............GL
I had a doctor tell me I had six months to live. I told him I could not pay his bill right away. He gave me another six months.................GLTA
just some longs ragging on the bashers.. its only a message board. Entertainment mostly, not much to do about anything really. The company is all that matters ................GL
For a long period of time, and that they even interbred. Brings avi.moron to mind, does it not?................GLTA
yes, it is his full time job. He is a stock bashing lackey for his boss. Not very good at his job, and based on his comments, I'd say he's definitely a dummy..................GLTA
Neither is he concerned about retail investors who cannot endure the challenge of patience. His job is not holding the hands of his investors, rather it is to create value for them and his company.
Personally, I like his style. I like his track record, and I like the company's potential............GLTA
The drops create more selling, but weak retail judging by volume. mm march down again, same pattern repeating. the big question, where are the buyers to offset it?
Summer hiatus, still to obscure, too cheap 35M m/cap, waiting on news? I don't know.
Just know fundamentals not the cause IMO, I remain vry bullish ............GL
If they have an update by then, more likely they will put it out just before a conference, as this was their timing in the past, often the day before.
Separating PR from presentation more effective IMO. Anyway, from my experience following RXI this was the norm...........GLTA
Worth the wait IMO. Two plus years of good DD by many experienced contributors. Not to lose sight its still P2. But with positive news, RXI will get the attention that has alluded this tiny company. Too much potential for a $35M m/cap company the way I see it.
Cauwenbergh is a tried and proven CEO. My bet is on him. No substitute for top management......GLTA